As of 2025-12-21, the EV/EBITDA ratio of ACADIA Pharmaceuticals Inc (ACAD) is -43.50. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Acadia's latest enterprise value is 4,336.93 mil USD. Acadia's TTM EBITDA according to its financial statements is -99.71 mil USD. Dividing these 2 quantities gives us the above Acadia EV/EBITDA ratio.
| Range | Selected | |
| Trailing P/E multiples | 13.8x - 15.2x | 14.6x |
| Forward P/E multiples | 16.3x - 18.9x | 17.0x |
| Fair Price | (6.61) - 29.89 | 9.93 |
| Upside | -124.3% - 10.0% | -63.4% |
| Date | EV/EBITDA |
| 2025-12-19 | -43.50 |
| 2025-12-18 | -42.55 |
| 2025-12-17 | -43.11 |
| 2025-12-16 | -42.88 |
| 2025-12-15 | -43.67 |
| 2025-12-12 | -43.48 |
| 2025-12-11 | -42.68 |
| 2025-12-10 | -42.90 |
| 2025-12-09 | -43.04 |
| 2025-12-08 | -42.82 |
| 2025-12-05 | -43.97 |
| 2025-12-04 | -42.46 |
| 2025-12-03 | -41.32 |
| 2025-12-02 | -40.56 |
| 2025-12-01 | -39.58 |
| 2025-11-28 | -39.90 |
| 2025-11-26 | -39.51 |
| 2025-11-25 | -38.80 |
| 2025-11-24 | -37.96 |
| 2025-11-21 | -37.39 |
| 2025-11-20 | -36.27 |
| 2025-11-19 | -36.61 |
| 2025-11-18 | -37.79 |
| 2025-11-17 | -38.15 |
| 2025-11-14 | -38.17 |
| 2025-11-13 | -37.52 |
| 2025-11-12 | -38.35 |
| 2025-11-11 | -37.66 |
| 2025-11-10 | -35.08 |
| 2025-11-07 | -35.71 |
| 2025-11-06 | -34.15 |
| 2025-11-05 | -35.30 |
| 2025-11-04 | -34.49 |
| 2025-11-03 | -35.37 |
| 2025-10-31 | -35.93 |
| 2025-10-30 | -36.00 |
| 2025-10-29 | -35.64 |
| 2025-10-28 | -35.79 |
| 2025-10-27 | -36.42 |
| 2025-10-24 | -34.77 |
| 2025-10-23 | -34.28 |
| 2025-10-22 | -33.71 |
| 2025-10-21 | -33.50 |
| 2025-10-20 | -32.94 |
| 2025-10-17 | -32.86 |
| 2025-10-16 | -32.40 |
| 2025-10-15 | -34.30 |
| 2025-10-14 | -31.96 |
| 2025-10-13 | -31.45 |
| 2025-10-10 | -31.45 |